These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Ga68-PSMA PET for lymph node staging in intermediate and high-risk prostate cancer patients undergoing robotic assisted radical prostatectomy. Spena G; Moretti TB; Dávila FS; Dos Anjos G; Khan I; Calace FP; Aveta A; Pandolfo SD; Tufano A; Izzo A; Farias A; Perdonà S; Maes K Minerva Urol Nephrol; 2024 Aug; 76(4):467-473. PubMed ID: 39051893 [TBL] [Abstract][Full Text] [Related]
8. Gallium-68-prostate-specific membrane antigen ( van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667 [TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of the performance of [ Abufaraj M; Grubmüller B; Zeitlinger M; Kramer G; Seitz C; Haitel A; Baltzer P; Hacker M; Wadsak W; Pfaff S; Wiatr T; Mitterhauser M; Shariat SF; Hartenbach M Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2169-2177. PubMed ID: 31254037 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic Accuracy of Cantiello F; Gangemi V; Cascini GL; Calabria F; Moschini M; Ferro M; Musi G; Butticè S; Salonia A; Briganti A; Damiano R Urology; 2017 Aug; 106():139-145. PubMed ID: 28438628 [TBL] [Abstract][Full Text] [Related]
11. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit. Maestroni UV; Campobasso D; Guarino G; Acampora A; Scarlattei M; Ziglioli F; Dinale F; Baldari G; Migliari S; Gasparro D; Ferretti S; Silini EM; Ruffini L Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288 [TBL] [Abstract][Full Text] [Related]
12. von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806 [TBL] [Abstract][Full Text] [Related]
16. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen ( Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951 [TBL] [Abstract][Full Text] [Related]
17. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Budäus L; Leyh-Bannurah SR; Salomon G; Michl U; Heinzer H; Huland H; Graefen M; Steuber T; Rosenbaum C Eur Urol; 2016 Mar; 69(3):393-6. PubMed ID: 26116958 [TBL] [Abstract][Full Text] [Related]
18. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398 [TBL] [Abstract][Full Text] [Related]
19. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard. Stabile A; Pellegrino A; Mazzone E; Cannoletta D; de Angelis M; Barletta F; Scuderi S; Cucchiara V; Gandaglia G; Raggi D; Necchi A; Karakiewicz P; Montorsi F; Briganti A Eur Urol Oncol; 2022 Feb; 5(1):1-17. PubMed ID: 34538770 [TBL] [Abstract][Full Text] [Related]
20. Comparison of Zhang Q; Zang S; Zhang C; Fu Y; Lv X; Zhang Q; Deng Y; Zhang C; Luo R; Zhao X; Wang W; Wang F; Guo H J Transl Med; 2017 Nov; 15(1):230. PubMed ID: 29115970 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]